Los Angeles Capital Management LLC Sells 51,670 Shares of ADMA Biologics Inc $ADMA

Los Angeles Capital Management LLC decreased its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 42.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 71,374 shares of the biotechnology company’s stock after selling 51,670 shares during the quarter. Los Angeles Capital Management LLC’s holdings in ADMA Biologics were worth $1,300,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ADMA. Nuveen LLC bought a new position in shares of ADMA Biologics during the first quarter worth approximately $93,543,000. Vaughan Nelson Investment Management L.P. acquired a new stake in ADMA Biologics during the second quarter worth approximately $32,786,000. Driehaus Capital Management LLC increased its stake in ADMA Biologics by 114.9% during the 1st quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company’s stock worth $58,460,000 after acquiring an additional 1,575,363 shares during the period. Invesco Ltd. increased its stake in ADMA Biologics by 13.9% during the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company’s stock worth $255,279,000 after acquiring an additional 1,570,649 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in ADMA Biologics by 152.7% in the 1st quarter. Russell Investments Group Ltd. now owns 1,632,675 shares of the biotechnology company’s stock valued at $32,392,000 after acquiring an additional 986,666 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $16.46 on Thursday. The firm’s 50 day simple moving average is $15.29 and its 200 day simple moving average is $17.73. The firm has a market capitalization of $3.93 billion, a price-to-earnings ratio of 19.14 and a beta of 0.40. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. The firm had revenue of $134.22 million during the quarter, compared to analysts’ expectations of $131.20 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The company’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.15 earnings per share. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings lowered ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.